Palmitoylethanolamide (PEA) is an endogenous fatty acid amide analogue of the endocannabinoid anandamine, from the N-acylethanolamines family of lipid mediators.

• PEA Liquid is micronised to a 20um-25um particle size using laser diffraction.

• Presented in a coconut-derived (MCT) lipid suspension for ease of compounding.

• 1mL contains 300mg PEA for easy dose calculation.

• Synthesised from palmitic acid from sustainably sourced palm oil.

• PEA liquid contains 99% pure PEA, which has been confirmed by purity testing.

• Pleasant natural orange flavour.

Each 1mL (28 drops) contains:

Palmitoylethanolamide (PEA) is a crystalline, highly lipophilic N-acylethanolamine (NAE), a class of naturally occurring mediators each composed of a fatty acid and ethanolamine; in turn classed as fatty acid ethanolamines (FAEs). The endocannabinoid, N-arachidonoylethanolamine (anandamide), and its congeners N-stearoylethanolamine and N-oleoylethanolamine, are also members of this family. PEA acts as an anandamine analogue.1 Anandamide was first isolated from pig brain and classed as the first endocannabinoid. N-acylethanolamines, such as PEA, do not show ligand activity for cannabinoid receptors, anandamide could be concomitantly produced as a by-product of non-endocannabinoid N-acylethanolamines.1 Because PEA is lipophilic and poorly water-soluble, its low dissolution rate in fluids can limit absorption and, therefore, biological responses. Thus, the particle size of PEA represents a crucial technology issue. 

Available clinical trials have utilised PEA products manufactured using several different types of micronisation processes, yielding varying results. Laser diffraction ultra-micronisation yields an altered crystalline PEA structure with higher energy content, resulting in superior biological efficacy compared to its native form.